Showing 1,261 - 1,280 results of 1,979 for search '"Sichuan"', query time: 0.08s Refine Results
  1. 1261
  2. 1262
  3. 1263

    External validation of the prediction model of intradialytic hypotension: a multicenter prospective cohort study by Yuhe Xiang, Guoting Ma, Qin Yang, Min Cao, Wenbin Xu, Lin Li, Qian Yang

    Published 2024-12-01
    “…The purpose of this study is to externally verify three IDH risk prediction models recently developed by Ma et al. and recalibrate, update and present the optimal model to improve the accuracy and applicability of the model in clinical environment.Methods A multicenter prospective cohort study of patients from 11 hemodialysis centers in Sichuan Province, China, was conducted using convenience sampling from March 2022 to July 2022, with a follow-up period of 1 month. …”
    Get full text
    Article
  4. 1264
  5. 1265
  6. 1266
  7. 1267
  8. 1268

    A novel framework unveiling the importance of heterogeneous selection and drift on the community structure of symbiotic microbial indicator taxa across altitudinal gradients in amp... by Jin Zhou, Zhidong Liu, Sishuo Wang, Jing Li, Lin Zhang, Ziyan Liao

    Published 2025-02-01
    “…Amphibian symbiotic microbes along an altitudinal gradient from Sichuan Province, China, were employed to examine the proposed statistical framework. …”
    Get full text
    Article
  9. 1269
  10. 1270
  11. 1271
  12. 1272
  13. 1273
  14. 1274
  15. 1275
  16. 1276

    Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial by Liu Y, Li X, Zhang M, Men Y, Wang Y, Zhu X, Zheng L

    Published 2025-01-01
    “…Yixian Liu,1,2,* Xiaoyu Li,1,2,* Mengyu Zhang,1,2 Yuchun Men,1,2 Ying Wang,1,2 Xiaohong Zhu,1,2 Li Zheng1,2 1Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China; 2Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Zheng, Cancer Center, West China Hospital, Sichuan University, No. 5 Telecom Road, Wuhou District, Chengdu, 610041, People’s Republic of China, Email zhengli@wchscu.cnPurpose: HA121-28, a novel multi-targeting tyrosine kinase inhibitor, has dual efficacy against tumor growth and neovascularization. …”
    Get full text
    Article
  17. 1277
  18. 1278
  19. 1279
  20. 1280